CUAMC
TVRD

China Universal Asset Management Company’s Tvardi Therapeutics TVRD Stock Holding History

China Universal Asset Management Company’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,000
Closed -$39K – 543
2025
Q3 		$39K Buy
+1,000
New +$28.5K ﹤0.01% 444
2023
Q4 		– Sell
-39
Closed -$2.33K – 486
2023
Q3 		$2.33K Buy
39
+19
+95% +$1.78K ﹤0.01% 427
2023
Q2 		$2K Hold
20
– – ﹤0.01% 425
2023
Q1 		$3.57K Buy
20
+5
+33% +$1.67K ﹤0.01% 402
2022
Q4 		$5.86K Buy
15
+1
+7% +$380 ﹤0.01% 279
2022
Q3 		$5K Buy
+14
New +$5.07K ﹤0.01% 279

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

China Universal Asset Management Company's TVRD Position: Q4 2025 in Review

China Universal Asset Management Company sold out of Tvardi Therapeutics (TVRD) in Q4 2025, closing a stake of 1,000 shares — an estimated $39K sold.

China Universal Asset Management Company first reported a position in TVRD in Q3 2022 and held it in 6 quarters. The position peaked at $39K in Q3 2025. 67 funds tracked by Wall St. Rank hold TVRD as of Q4 2025.

  • China Universal Asset Management Company reported no remaining Tvardi Therapeutics position as of Q4 2025 after selling out during the quarter.
  • China Universal Asset Management Company sold 1,000 Tvardi Therapeutics shares in Q4 2025, an estimated $39K.
  • China Universal Asset Management Company first reported a position in Tvardi Therapeutics in Q3 2022 and held it in 6 quarters.
  • China Universal Asset Management Company's Tvardi Therapeutics position peaked at $39K in Q3 2025.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2025.

Based on China Universal Asset Management Company's 13F filing for Q4 2025, filed 29 Jan 2026.